Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

PloS one

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Sertić J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.
PMID: 28207884
PLoS One. 2017 Feb 16;12(2):e0172595. doi: 10.1371/journal.pone.0172595. eCollection 2017.

[This corrects the article DOI: 10.1371/journal.pone.0162866.].

Cite
Mizzi C, Dalabira E, Kumuthini J, et al. Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS One. 2017;12(2):e0172595doi: 10.1371/journal.pone.0172595.
Mizzi, C., Dalabira, E., Kumuthini, J., Dzimiri, N., Balogh, I., Başak, N., Böhm, R., Borg, J., Borgiani, P., Bozina, N., Bruckmueller, H., Burzynska, B., Carracedo, A., Cascorbi, I., Deltas, C., Dolzan, V., Fenech, A., Grech, G., Kasiulevicius, V., Kádaši, �. �., Kučinskas, V., Khusnutdinova, E., Loukas, Y. L., Macek, M., Makukh, H., Mathijssen, R., Mitropoulos, K., Mitropoulou, C., Novelli, G., Papantoni, I., Pavlovic, S., Saglio, G., Sertić, J., Stojiljkovic, M., Stubbs, A. P., Squassina, A., Torres, M., Turnovec, M., van Schaik, R. H., Voskarides, K., Wakil, S. M., Werk, A., Del Zompo, M., Zukic, B., Katsila, T., Lee, M. T., Motsinger-Rief, A., Mc Leod, H. L., van der Spek, P. J., & Patrinos, G. P. (2017). Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PloS one, 12(2), e0172595. https://doi.org/10.1371/journal.pone.0172595
Mizzi, Clint, et al. "Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics." PloS one vol. 12,2 (2017): e0172595. doi: https://doi.org/10.1371/journal.pone.0172595
Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Sertić J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP. Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS One. 2017 Feb 16;12(2):e0172595. doi: 10.1371/journal.pone.0172595. eCollection 2017. PMID: 28207884; PMCID: PMC5313168.
Copy Download .nbib Format: NLM
Altered expression of miR-142, miR-155, miR-499a and of their putative common target .

Epigenomics

Latini A, Ciccacci C, Benedittis G, Novelli L, Ceccarelli F, Conti F, Novelli G, Perricone C, Borgiani P.
PMID: 33337917
Epigenomics. 2021 Jan;13(1):5-13. doi: 10.2217/epi-2020-0278. Epub 2020 Dec 18.

No abstract available.

Cite
Latini A, Ciccacci C, Benedittis G, et al. Altered expression of miR-142, miR-155, miR-499a and of their putative common target . Epigenomics. 2020;13(1):5-13doi: 10.2217/epi-2020-0278.
Latini, A., Ciccacci, C., Benedittis, G., Novelli, L., Ceccarelli, F., Conti, F., Novelli, G., Perricone, C., & Borgiani, P. (2021). Altered expression of miR-142, miR-155, miR-499a and of their putative common target . Epigenomics, 13(1), 5-13. https://doi.org/10.2217/epi-2020-0278
Latini, Andrea, et al. "Altered expression of miR-142, miR-155, miR-499a and of their putative common target ." Epigenomics vol. 13,1 (2021): 5-13. doi: https://doi.org/10.2217/epi-2020-0278
Latini A, Ciccacci C, Benedittis G, Novelli L, Ceccarelli F, Conti F, Novelli G, Perricone C, Borgiani P. Altered expression of miR-142, miR-155, miR-499a and of their putative common target . Epigenomics. 2021 Jan;13(1):5-13. doi: 10.2217/epi-2020-0278. Epub 2020 Dec 18. PMID: 33337917.
Copy Download .nbib Format: NLM
Genetics, Epigenetics, and Gender Impact in Axial-Spondyloarthritis Susceptibility: An Update on Genetic Polymorphisms and Their Sex Related Associations.

Frontiers in genetics

Chimenti MS, Perricone C, D'Antonio A, Ferraioli M, Conigliaro P, Triggianese P, Ciccacci C, Borgiani P, Perricone R.
PMID: 34447407
Front Genet. 2021 Aug 10;12:671976. doi: 10.3389/fgene.2021.671976. eCollection 2021.

Spondyloarthritis (SpA) is a group of chronic inflammatory rheumatic disease that can be divided into predominantly axial or predominantly peripheral involvement, with or without associated psoriasis, inflammatory bowel disease or previous infection. Axial SpA (axSpA) encompasses ankylosing spondylitis (AS)...

Cite
Chimenti MS, Perricone C, D'Antonio A, et al. Genetics, Epigenetics, and Gender Impact in Axial-Spondyloarthritis Susceptibility: An Update on Genetic Polymorphisms and Their Sex Related Associations. Front Genet. 2021;12:671976doi: 10.3389/fgene.2021.671976.
Chimenti, M. S., Perricone, C., D'Antonio, A., Ferraioli, M., Conigliaro, P., Triggianese, P., Ciccacci, C., Borgiani, P., & Perricone, R. (2021). Genetics, Epigenetics, and Gender Impact in Axial-Spondyloarthritis Susceptibility: An Update on Genetic Polymorphisms and Their Sex Related Associations. Frontiers in genetics, 12671976. https://doi.org/10.3389/fgene.2021.671976
Chimenti, Maria Sole, et al. "Genetics, Epigenetics, and Gender Impact in Axial-Spondyloarthritis Susceptibility: An Update on Genetic Polymorphisms and Their Sex Related Associations." Frontiers in genetics vol. 12 (2021): 671976. doi: https://doi.org/10.3389/fgene.2021.671976
Chimenti MS, Perricone C, D'Antonio A, Ferraioli M, Conigliaro P, Triggianese P, Ciccacci C, Borgiani P, Perricone R. Genetics, Epigenetics, and Gender Impact in Axial-Spondyloarthritis Susceptibility: An Update on Genetic Polymorphisms and Their Sex Related Associations. Front Genet. 2021 Aug 10;12:671976. doi: 10.3389/fgene.2021.671976. eCollection 2021. PMID: 34447407; PMCID: PMC8383732.
Copy Download .nbib Format: NLM
Age-related macular degeneration: insights into inflammatory genes.

Journal of ophthalmology

Cascella R, Ragazzo M, Strafella C, Missiroli F, Borgiani P, Angelucci F, Marsella LT, Cusumano A, Novelli G, Ricci F, Giardina E.
PMID: 25478207
J Ophthalmol. 2014;2014:582842. doi: 10.1155/2014/582842. Epub 2014 Nov 12.

Age-related macular degeneration (AMD) is a progressive neurodegenerative disease that affects approximately 8.7% of elderly people worldwide (>55 years old). AMD is characterized by a multifactorial aetiology that involves several genetic and environmental risk factors (genes, ageing, smoking, family...

Cite
Cascella R, Ragazzo M, Strafella C, et al. Age-related macular degeneration: insights into inflammatory genes. J Ophthalmol. 2014;2014:582842doi: 10.1155/2014/582842.
Cascella, R., Ragazzo, M., Strafella, C., Missiroli, F., Borgiani, P., Angelucci, F., Marsella, L. T., Cusumano, A., Novelli, G., Ricci, F., & Giardina, E. (2014). Age-related macular degeneration: insights into inflammatory genes. Journal of ophthalmology, 2014582842. https://doi.org/10.1155/2014/582842
Cascella, Raffaella, et al. "Age-related macular degeneration: insights into inflammatory genes." Journal of ophthalmology vol. 2014 (2014): 582842. doi: https://doi.org/10.1155/2014/582842
Cascella R, Ragazzo M, Strafella C, Missiroli F, Borgiani P, Angelucci F, Marsella LT, Cusumano A, Novelli G, Ricci F, Giardina E. Age-related macular degeneration: insights into inflammatory genes. J Ophthalmol. 2014;2014:582842. doi: 10.1155/2014/582842. Epub 2014 Nov 12. PMID: 25478207; PMCID: PMC4247975.
Copy Download .nbib Format: NLM
Pharmacogenomics in Parkinson's disease: which perspective for developing a personalized medicine?.

Neural regeneration research

Ciccacci C, Borgiani P.
PMID: 30531077
Neural Regen Res. 2019 Jan;14(1):75-76. doi: 10.4103/1673-5374.243706.

No abstract available.

Cite
Ciccacci C, Borgiani P. Pharmacogenomics in Parkinson's disease: which perspective for developing a personalized medicine?. Neural Regen Res. 2019;14(1):75-76doi: 10.4103/1673-5374.243706.
Ciccacci, C., & Borgiani, P. (2019). Pharmacogenomics in Parkinson's disease: which perspective for developing a personalized medicine?. Neural regeneration research, 14(1), 75-76. https://doi.org/10.4103/1673-5374.243706
Ciccacci, Cinzia, and Borgiani, Paola. "Pharmacogenomics in Parkinson's disease: which perspective for developing a personalized medicine?." Neural regeneration research vol. 14,1 (2019): 75-76. doi: https://doi.org/10.4103/1673-5374.243706
Ciccacci C, Borgiani P. Pharmacogenomics in Parkinson's disease: which perspective for developing a personalized medicine?. Neural Regen Res. 2019 Jan;14(1):75-76. doi: 10.4103/1673-5374.243706. PMID: 30531077; PMCID: PMC6263000.
Copy Download .nbib Format: NLM
VDR Polymorphisms in Autoimmune Connective Tissue Diseases: Focus on Italian Population.

Journal of immunology research

Latini A, De Benedittis G, Perricone C, Colafrancesco S, Conigliaro P, Ceccarelli F, Chimenti MS, Novelli L, Priori R, Conti F, Ciccacci C, Borgiani P.
PMID: 34977255
J Immunol Res. 2021 Dec 23;2021:5812136. doi: 10.1155/2021/5812136. eCollection 2021.

Vitamin D is an important hormone involved in various physiologic processes, and its activity is linked to binding with vitamin D receptor (VDR). Genetic polymorphisms in the VDR gene could modulate the expression or function of the receptor and,...

Cite
Latini A, De Benedittis G, Perricone C, et al. VDR Polymorphisms in Autoimmune Connective Tissue Diseases: Focus on Italian Population. J Immunol Res. 2021;2021:5812136doi: 10.1155/2021/5812136.
Latini, A., De Benedittis, G., Perricone, C., Colafrancesco, S., Conigliaro, P., Ceccarelli, F., Chimenti, M. S., Novelli, L., Priori, R., Conti, F., Ciccacci, C., & Borgiani, P. (2021). VDR Polymorphisms in Autoimmune Connective Tissue Diseases: Focus on Italian Population. Journal of immunology research, 20215812136. https://doi.org/10.1155/2021/5812136
Latini, Andrea, et al. "VDR Polymorphisms in Autoimmune Connective Tissue Diseases: Focus on Italian Population." Journal of immunology research vol. 2021 (2021): 5812136. doi: https://doi.org/10.1155/2021/5812136
Latini A, De Benedittis G, Perricone C, Colafrancesco S, Conigliaro P, Ceccarelli F, Chimenti MS, Novelli L, Priori R, Conti F, Ciccacci C, Borgiani P. VDR Polymorphisms in Autoimmune Connective Tissue Diseases: Focus on Italian Population. J Immunol Res. 2021 Dec 23;2021:5812136. doi: 10.1155/2021/5812136. eCollection 2021. PMID: 34977255; PMCID: PMC8718283.
Copy Download .nbib Format: NLM
A Novel .

Biomedicines

Di Fusco D, Marafini I, Stolfi C, Troncone E, Onali S, Lolli E, Caprioli F, Mazza S, Raffaella C, Manzo L, Borgiani P, Giuffrida P, Di Sabatino A, Monteleone I, Monteleone G.
PMID: 32707955
Biomedicines. 2020 Jul 22;8(8). doi: 10.3390/biomedicines8080234.

BACKGROUND: Down-regulation of Smad7 with a specific Smad7 antisense (AS) oligonucleotide-containing oral drug (Mongersen) was effective in pre-clinical studies and initial clinical trials in Crohn's disease (CD) patients. A recent phase 3 trial was discontinued due to an apparent...

Cite
Di Fusco D, Marafini I, Stolfi C, et al. A Novel . Biomedicines. 2020;8(8)doi: 10.3390/biomedicines8080234.
Di Fusco, D., Marafini, I., Stolfi, C., Troncone, E., Onali, S., Lolli, E., Caprioli, F., Mazza, S., Raffaella, C., Manzo, L., Borgiani, P., Giuffrida, P., Di Sabatino, A., Monteleone, I., & Monteleone, G. (2020). A Novel . Biomedicines, 8(8), . https://doi.org/10.3390/biomedicines8080234
Di Fusco, Davide, et al. "A Novel ." Biomedicines vol. 8,8 (2020). doi: https://doi.org/10.3390/biomedicines8080234
Di Fusco D, Marafini I, Stolfi C, Troncone E, Onali S, Lolli E, Caprioli F, Mazza S, Raffaella C, Manzo L, Borgiani P, Giuffrida P, Di Sabatino A, Monteleone I, Monteleone G. A Novel . Biomedicines. 2020 Jul 22;8(8). doi: 10.3390/biomedicines8080234. PMID: 32707955; PMCID: PMC7460430.
Copy Download .nbib Format: NLM
Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants.

Oncotarget

Cascella R, Strafella C, Longo G, Ragazzo M, Manzo L, De Felici C, Errichiello V, Caputo V, Viola F, Eandi CM, Staurenghi G, Cusumano A, Mauriello S, Marsella LT, Ciccacci C, Borgiani P, Sangiuolo F, Novelli G, Ricci F, Giardina E.
PMID: 29487693
Oncotarget. 2017 Dec 12;9(8):7812-7821. doi: 10.18632/oncotarget.23241. eCollection 2018 Jan 30.

Age-related Macular Degeneration (AMD) represents one of the most sight-threatening diseases in developed countries that substantially impacts the patients' lifestyle by compromising everyday activities, such as reading and driving. In this context, understanding the prevalence, burden, and population-specific risk/protective...

Cite
Cascella R, Strafella C, Longo G, et al. Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants. Oncotarget. 2017;9(8):7812-7821doi: 10.18632/oncotarget.23241.
Cascella, R., Strafella, C., Longo, G., Ragazzo, M., Manzo, L., De Felici, C., Errichiello, V., Caputo, V., Viola, F., Eandi, C. M., Staurenghi, G., Cusumano, A., Mauriello, S., Marsella, L. T., Ciccacci, C., Borgiani, P., Sangiuolo, F., Novelli, G., Ricci, F., & Giardina, E. (2018). Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants. Oncotarget, 9(8), 7812-7821. https://doi.org/10.18632/oncotarget.23241
Cascella, Raffaella, et al. "Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants." Oncotarget vol. 9,8 (2018): 7812-7821. doi: https://doi.org/10.18632/oncotarget.23241
Cascella R, Strafella C, Longo G, Ragazzo M, Manzo L, De Felici C, Errichiello V, Caputo V, Viola F, Eandi CM, Staurenghi G, Cusumano A, Mauriello S, Marsella LT, Ciccacci C, Borgiani P, Sangiuolo F, Novelli G, Ricci F, Giardina E. Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants. Oncotarget. 2017 Dec 12;9(8):7812-7821. doi: 10.18632/oncotarget.23241. eCollection 2018 Jan 30. PMID: 29487693; PMCID: PMC5814260.
Copy Download .nbib Format: NLM
Genetic tests and genomic biomarkers: regulation, qualification and validation.

Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases

Novelli G, Ciccacci C, Borgiani P, Papaluca Amati M, Abadie E.
PMID: 22460999
Clin Cases Miner Bone Metab. 2008 May;5(2):149-54.

The identification of new risk factors for specific diseases is an enduring theme in medical research. Advances in molecular biology, genetics, and computational biology are accelerating the pace of this work. The research seeks to increase our understanding of...

Cite
Novelli G, Ciccacci C, Borgiani P, et al. Genetic tests and genomic biomarkers: regulation, qualification and validation. Clin Cases Miner Bone Metab. 2008;5(2):149-54
Novelli, G., Ciccacci, C., Borgiani, P., Papaluca Amati, M., & Abadie, E. (2008). Genetic tests and genomic biomarkers: regulation, qualification and validation. Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases, 5(2), 149-54.
Novelli, Giuseppe, et al. "Genetic tests and genomic biomarkers: regulation, qualification and validation." Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases vol. 5,2 (2008): 149-54.
Novelli G, Ciccacci C, Borgiani P, Papaluca Amati M, Abadie E. Genetic tests and genomic biomarkers: regulation, qualification and validation. Clin Cases Miner Bone Metab. 2008 May;5(2):149-54. PMID: 22460999; PMCID: PMC2781197.
Copy Download .nbib Format: NLM
Genetic tests and genomic biomarkers: regulation, qualification and validation.

Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases

Novelli G, Ciccacci C, Borgiani P, Papaluca Amati M, Abadie E.
PMID: 22460999
Clin Cases Miner Bone Metab. 2008 May;5(2):149-54.

The identification of new risk factors for specific diseases is an enduring theme in medical research. Advances in molecular biology, genetics, and computational biology are accelerating the pace of this work. The research seeks to increase our understanding of...

Cite
Novelli G, Ciccacci C, Borgiani P, et al. Genetic tests and genomic biomarkers: regulation, qualification and validation. Clin Cases Miner Bone Metab. 2008;5(2):149-54
Novelli, G., Ciccacci, C., Borgiani, P., Papaluca Amati, M., & Abadie, E. (2008). Genetic tests and genomic biomarkers: regulation, qualification and validation. Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases, 5(2), 149-54.
Novelli, Giuseppe, et al. "Genetic tests and genomic biomarkers: regulation, qualification and validation." Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases vol. 5,2 (2008): 149-54.
Novelli G, Ciccacci C, Borgiani P, Papaluca Amati M, Abadie E. Genetic tests and genomic biomarkers: regulation, qualification and validation. Clin Cases Miner Bone Metab. 2008 May;5(2):149-54. PMID: 22460999; PMCID: PMC2781197.
Copy Download .nbib Format: NLM
Precision Medicine in Non-Communicable Diseases.

High-throughput

Novelli G, Biancolella M, Latini A, Spallone A, Borgiani P, Papaluca M.
PMID: 32046063
High Throughput. 2020 Feb 07;9(1). doi: 10.3390/ht9010003.

The increase in life expectancy during the 20th century ranks as one of society's greatest achievements, with massive growth in the numbers and proportion of the elderly, virtually occurring in every country of the world. The burden of chronic...

Cite
Novelli G, Biancolella M, Latini A, et al. Precision Medicine in Non-Communicable Diseases. High Throughput. 2020;9(1)doi: 10.3390/ht9010003.
Novelli, G., Biancolella, M., Latini, A., Spallone, A., Borgiani, P., & Papaluca, M. (2020). Precision Medicine in Non-Communicable Diseases. High-throughput, 9(1), . https://doi.org/10.3390/ht9010003
Novelli, Giuseppe, et al. "Precision Medicine in Non-Communicable Diseases." High-throughput vol. 9,1 (2020). doi: https://doi.org/10.3390/ht9010003
Novelli G, Biancolella M, Latini A, Spallone A, Borgiani P, Papaluca M. Precision Medicine in Non-Communicable Diseases. High Throughput. 2020 Feb 07;9(1). doi: 10.3390/ht9010003. PMID: 32046063; PMCID: PMC7151056.
Copy Download .nbib Format: NLM
Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy.

Frontiers in genetics

Passarelli C, Selvatici R, Carrieri A, Di Raimo FR, Falzarano MS, Fortunato F, Rossi R, Straub V, Bushby K, Reza M, Zharaieva I, D'Amico A, Bertini E, Merlini L, Sabatelli P, Borgiani P, Novelli G, Messina S, Pane M, Mercuri E, Claustres M, Tuffery-Giraud S, Aartsma-Rus A, Spitali P, T'Hoen PAC, Lochmüller H, Strandberg K, Al-Khalili C, Kotelnikova E, Lebowitz M, Schwartz E, Muntoni F, Scapoli C, Ferlini A.
PMID: 32719714
Front Genet. 2020 Jul 03;11:605. doi: 10.3389/fgene.2020.00605. eCollection 2020.

BACKGROUND: Duchenne muscular dystrophy (DMD) is a rare and severe X-linked muscular dystrophy in which the standard of care with variable outcome, also due to different drug response, is chronic off-label treatment with corticosteroids (CS). In order to search...

Cite
Passarelli C, Selvatici R, Carrieri A, et al. Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy. Front Genet. 2020;11:605doi: 10.3389/fgene.2020.00605.
Passarelli, C., Selvatici, R., Carrieri, A., Di Raimo, F. R., Falzarano, M. S., Fortunato, F., Rossi, R., Straub, V., Bushby, K., Reza, M., Zharaieva, I., D'Amico, A., Bertini, E., Merlini, L., Sabatelli, P., Borgiani, P., Novelli, G., Messina, S., Pane, M., Mercuri, E., Claustres, M., Tuffery-Giraud, S., Aartsma-Rus, A., Spitali, P., T'Hoen, P. A. C., Lochmüller, H., Strandberg, K., Al-Khalili, C., Kotelnikova, E., Lebowitz, M., Schwartz, E., Muntoni, F., Scapoli, C., & Ferlini, A. (2020). Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy. Frontiers in genetics, 11605. https://doi.org/10.3389/fgene.2020.00605
Passarelli, Chiara, et al. "Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy." Frontiers in genetics vol. 11 (2020): 605. doi: https://doi.org/10.3389/fgene.2020.00605
Passarelli C, Selvatici R, Carrieri A, Di Raimo FR, Falzarano MS, Fortunato F, Rossi R, Straub V, Bushby K, Reza M, Zharaieva I, D'Amico A, Bertini E, Merlini L, Sabatelli P, Borgiani P, Novelli G, Messina S, Pane M, Mercuri E, Claustres M, Tuffery-Giraud S, Aartsma-Rus A, Spitali P, T'Hoen PAC, Lochmüller H, Strandberg K, Al-Khalili C, Kotelnikova E, Lebowitz M, Schwartz E, Muntoni F, Scapoli C, Ferlini A. Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy. Front Genet. 2020 Jul 03;11:605. doi: 10.3389/fgene.2020.00605. eCollection 2020. PMID: 32719714; PMCID: PMC7350910.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries